close

TreeFrog Therapeutics opens technological hub in Kobe, Japan, to drive partnerships opportunities in the field of iPSC-derived cell therapies

TreeFrog Therapeutics opens technological hub in Kobe, Japan, to drive partnerships opportunities in the field of iPSC-derived cell therapies TreeFrog Therapeutics, a French-based biotech company aimed at making safer, more efficient and more affordable cell therapies based on induced pluripotent stem cells (iPSCs), announced the incorporation of its Japanese subsidiary…..

Novasep and PharmaZell become one group

Novasep, a major CDMO focused on complex small molecules and antibody-drug conjugates (ADCs), and PharmaZell, a leading supplier of highly resilient and specialty APIs, have just closed their merger, following exclusive negotiations initiated in September 2021. This strategic merger creates a technology driven, leading Franco-German CDMO and API manufacturer. Novasep’s…..

Novartis expands Zolgensma® manufacturing capacity with approval of multi-product North Carolina facility

Novartis expands Zolgensma® manufacturing capacity with approval of multi-product North Carolina facility   The FDA has granted commercial licensure approval for Novartis' Durham, N.C. site, a multi-product gene therapy manufacturing facility. This approval allows the state-of-the-art, 170,000 square-foot facility to make, test and release commercial Zolgensma®, as well as produce…..

Microbiota medicine: towards clinical revolution

Microbiota medicine: towards clinical revolution 21 high-level authors and members of the International Society of Microbiota, coming from 8 countries and more than 10 reputable institutions published a new strategic report titled “Microbiota medicine: towards clinical revolution”. Published in the Journal of Translational Medicine, this stunning review confirms that microbiota…..